Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer
| Status: | Archived |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2008 |
| End Date: | January 2012 |
A Pilot Study of MK-0752 in Combination With Tamoxifen or Letrozole in Patients With Early Stage Breast Cancer Prior to Surgery
The purpose of this research project is to study the effect of a research (investigational)
drug, MK-0752 combined with either tamoxifen or letrozole on breast cancer cells.
Tamoxifen and letrozole are standard hormone treatments used to treat breast cancers that
are positive for the estrogen receptor. However, over time the breast cancer cells can
become resistant to tamoxifen and letrozole. MK-0752 is in a class of drugs called gamma
secretase inhibitors. Gamma secretase inhibitors may play a role in reversing the
resistance to drugs such as tamoxifen and letrozole.
OBJECTIVES
To evaluate the safety and tolerability of the gamma-secretase inhibitor MK-0752 in the
pre-surgical setting in patients with early stage, estrogen receptor (ER) positive breast
cancer, in combination with tamoxifen or an aromatase inhibitor (AI).
To establish the feasibility and success of multi-laboratory collaborations in evaluating
clinical specimens and biomarker testing.
To provide preliminary data on the impact of MK-0752 on a panel of biomarkers involved in
the notch signaling pathway.
We found this trial at
1
site
2160 S. First Ave.
Maywood, Illinois 60153
Maywood, Illinois 60153
888-584-7888
Cardinal Bernardin Cancer Center at Loyola University Medical Center The Cardinal Bernardin Cancer Center is...
Click here to add this to my saved trials
